Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Harbour BioMed
Deal Size : $970.0 million
Deal Type : Licensing Agreement
Harbour BioMed Licenses HBM9378 to Windward Bio for Immunological Diseases
Details : Under the licensing agreement, Windward Bio is granted an exclusive license to manufacture, and commercialize WIN378 (HBM-9378) globally, excluding Greater China.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $45.0 million
January 10, 2025
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Harbour BioMed
Deal Size : $970.0 million
Deal Type : Licensing Agreement
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : OrbiMed Advisors
Deal Size : $200.0 million
Deal Type : Series A Financing
Windward Bio Raises $200M to Advance Long-Acting Anti-TSLP Therapy
Details : The financing aims to advance the clinical development of WIN378 (HBM-9378), which is being evaluated for the treatment of severe asthma & chronic obstructive pulmonary disease.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 10, 2025
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : OrbiMed Advisors
Deal Size : $200.0 million
Deal Type : Series A Financing
Reset All
